CLSI M45

Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria, 3rd Edition

This guideline informs clinical, public health, and research laboratories on susceptibility testing of infrequently isolated or fastidious bacteria that are not included in CLSI documents M02, M07, or M100. Antimicrobial agent selection, test interpretation, and quality control are addressed.

This edition of the document was corrected in March 2016, August 2016, and June 2017 and updated in August 2016. Read the full correction and update notices by accessing the links above, and learn more about our corrections process here.

More Details

Member price:

List Price:

Add to Cart

Details

Chairholder: Janet A. Hindler, MCLS, MT(ASCP) and Sandra S. Richter, MD, D(ABMM)

Date of Publication: October 2, 2015

Order Code PDF: CLSI M45Ed3E
ISBN Number: 1-56238-918-1

Order Code Print: CLSI M45Ed3
ISBN Number: 1-56238-917-3

Edition: Third

Pages: 120

CLSI M45 Additional Details

The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.

CLSI M45 Abstract

If a bacterial pathogen’s susceptibility to antimicrobial agents cannot be predicted based on the identity of the organism alone, in vitro antimicrobial susceptibility testing of the isolated organism may be indicated. Susceptibility testing is particularly necessary in those situations in which the etiological agent belongs to a bacterial species for which resistance to commonly used antimicrobial agents has been documented, or could arise.